VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine

Recent Posts

• Vaccitech Announces Pricing of Initial Public Offering
• Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
• Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
• Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
• Vaccitech Appoints Two Independent Board Directors